title: Nanoparticle-mediated gene delivery to tumour neovasculature.
abstract: The alpha(v)beta(3) integrin is a potential pharmacological target for anti-angiogenic therapy. A recent report describes the use of alpha(v)beta(3)-targeted nanoparticles to deliver a gene to tumour vasculature selectively. This resulted in substantial tumour regression in several experimental mouse tumour models. Hence, this approach has great potential for the treatment of human cancer.
authors.affiliation: Cell Adhesion and Disease Laboratory, Cancer Research UK, Richard Dimbleby Department of Cancer Research, St. Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK.
authors.forename: Andrew R
authors.initials: AR
authors.lastname: Reynolds
authors.forename: S
authors.initials: S
authors.lastname: Moein Moghimi
authors.forename: Kairbaan
authors.initials: K
authors.lastname: Hodivala-Dilke
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D018014:Gene Transfer Techniques; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000378:metabolism*; D008958:Models, Molecular; D036103:Nanotechnology; D009369:Neoplasms / Q000098:blood supply* / Q000628:therapy*; D009389:Neovascularization, Pathologic
chemical_list: D020533:Angiogenesis Inhibitors; D039302:Integrin alphaVbeta3